Abstract
Nearly every drug may cause changes to ocular tissues through a variety of mechanisms. Medication overdoses, drug-drug interactions but also chronic administration of medications at the recommended doses may lead to ocular toxicity. The ocular side effects, screening for eye toxicity and treatment guidelines for anti-inflammatory and immunosuppressive drugs commonly used by rheumatologists are reviewed herein.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antimalarials / adverse effects
-
Antimalarials / therapeutic use
-
Antimetabolites / adverse effects
-
Antimetabolites / therapeutic use
-
Antirheumatic Agents / adverse effects*
-
Antirheumatic Agents / therapeutic use*
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / therapeutic use
-
Diphosphonates / adverse effects
-
Diphosphonates / therapeutic use
-
Drug Interactions
-
Eye Diseases / chemically induced*
-
Humans
-
Rheumatic Diseases / drug therapy*
-
Sulfasalazine / adverse effects
-
Sulfasalazine / therapeutic use
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antimalarials
-
Antimetabolites
-
Antirheumatic Agents
-
Bone Density Conservation Agents
-
Diphosphonates
-
Sulfasalazine